| Montelukast Sodium Basic information | |
| Product Name: | Montelukast Sodium |
| Synonyms: | singulair;MONTELUKASTNA;MONTELUKASTSODIUM;mk-476;2-[1-[[1-[3-[2-[(7-chloro-2-quinolyl)]vinyl]phenyl]-3-[2-(1-hydroxy-1-methyl-ethyl)phenyl]-propyl]sulfanylmethyl]cyclopropyl]aceticacidsodChemicalbookiumsalt;1-[1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic;MK-476,Singulair;Montelukast,SodiumSalt |
| CAS: | 151767-02-1 |
| MF: | C35H35ClNNaO3S |
| MW: | 608.17 |
| EINECS: | 604-813-7 |
| Product Categories: | Pharmaceutical raw materials; Intermediates; Pharmaceutical intermediate; Reference substance; Medical raw materials; Traditional Chinese medicine reference substance; Medical raw materials; Active pharmaceutical ingredients. Small molecule inhibitor; Pharmaceutical raw materials; Small molecule inhibitors, natural products; The raw material; Antiasthmatic drug substance; Pharmaceutical raw materials anti-asthma raw materials; IDL products; 11. Pharmaceutical products; Antiasthmatic drugs; Antibody-secondary antibody; Chemical intermediates |
| Introduction | Cysteinyl leukotrienes (LTC4, LTD4, LTE4) is a eicosane-type substance released by various kinds of cells including mast cells and eosinophils with strong inflammatory effect. These important asthma pre-inflammatory mediators can bind to the Cysteinyl leukotriene receptors (CysLT) identified in the human airways, resulting in a variety of airway responses including bronchoconstriction, mucus secretion, increased vascular permeability, and eosinophil accumulation |
| Application | A selective leukotriene D4-receptor antagonist. Used as an antiasthmatic |
| Montelukast Sodium Chemical Properties | |
| Melting point | 115 °C(dec.) |
| optical activity | [α]/D +90 to +106° in methanol (c=1) |
| Storage condition | 2-8°C |
| Solubility | DMSO: ≥8mg/mL at 60°C |
| form | Powder. |
| color | white to tan |
